NM283: Phase I/II data

In a double-blind, placebo-controlled, dose-escalating U.S. Phase I/II trial in 82 evaluable patients, NM283 was well tolerated and gave a mean HCV RNA reduction of 1.1 log10 IU/ml (92%) in those who ...